Immatics N.V.
Immatics N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing T-cell–redirecting cancer immunotherapies. The company works on proprietary TCR-based and bispecific approaches designed to target tumor-associated antigens across multiple solid tumor indications, with operations spanning Europe and the United States through its corporate group.
Fiscal year 2025 · change from previous year
Development 2022–2025
Business
Share of revenueEngineered therapies that use T-cell receptors to recognize tumor antigens.
T-cell–redirecting molecules designed to engage immune cells against tumors.
Partnered research, development, and licensing activities around oncology targets.
Target identification and early-stage validation work for future drug candidates.
Customers
Immatics does not sell a conventional commercial product portfolio; its primary counterparties are pharmaceutical partners, research collaborators, and clinical trial sites. Its programs are ultimately aimed at patients with solid tumors, but near-term economic activity is driven by collaboration structures, development agreements, and clinical research relationships.
Buy access to proprietary targets, therapeutic candidates, or collaboration rights for oncology development.
Engage in platform or program collaborations to expand their immuno-oncology pipelines.
Run studies and provide patient recruitment and data generation for pipeline programs.
Receive experimental therapies in solid tumor studies as part of clinical development.
Support target discovery, biomarker work, and translational research around tumor antigens.
Strategy
Immatics’ strategy centers on advancing T-cell redirecting therapies from discovery into clinical proof-of-concept, with emphasis on tumor antigens that can support multiple solid tumor programs. The company also uses collaborations and partnering to extend its platform, share development risk, and broaden the reach of its antigen-discovery capabilities.
Human data are needed to validate the platform and support partnering or internal development.
Unique antigen presentation and patient-selection logic can improve therapeutic specificity.
Collaborations can provide capital, expertise, and external validation for pipeline assets.
Geography
Immatics is organized as a cross-border biopharmaceutical group with roots in Europe and a corporate presence in the United States. Its research, development, and investor-relations footprint spans multiple countries, while clinical development is conducted through international trial networks rather than a single domestic market.
Risks
As a clinical-stage oncology company, Immatics faces substantial development risk because its programs must show safety, target engagement, and efficacy in humans before becoming commercially viable. The business also depends on capital access, scientific differentiation, and complex accounting estimates tied to R&D and share-based compensation.
- Clinical development failureImpact: CriticalLikelihood: High
Programs must demonstrate safety and efficacy in patients, and oncology trials often fail in later stages.
Exposure: Lead TCR and bispecific programs
- Scientific and target-validation riskImpact: HighLikelihood: High
Therapies rely on tumor antigen presentation and immune recognition that may not translate consistently across patients.
Exposure: TCR-based platform and biomarker strategy
- Financing and partner-dependence riskImpact: HighLikelihood: High
Clinical-stage biopharma typically needs external funding and collaboration revenue to sustain development.
Exposure: Research and clinical pipeline funding
- Competition in oncology immunotherapyImpact: MediumLikelihood: High
Multiple companies are pursuing T-cell redirection, making differentiation and deal access important.
Exposure: Pipeline positioning and partnering
Accounting
Judgemental itemsCollaboration and licensing arrangements may require allocation across performance obligations and milestones.
Impact: Can shift revenue timing between periods
Clinical and preclinical spending must be classified and accrued based on project stage and vendor estimates.
Impact: Affects operating loss and comparability
Equity awards to employees create non-cash expense that can be material for a biotech company.
Impact: Influences reported personnel costs and loss
Cross-border operations and loss carryforwards require estimation of tax assets and liabilities.
Impact: Can affect the balance sheet and net loss
Similar listed companies
Publicly listed companies with a comparable business focus.
TScan Therapeutics, Inc.
TCRX · Biological Products, (No Diagnostic Substances)
TScan Therapeutics is a U.S.-based clinical-stage biotechnology company developing T cell receptor-engineered T cell, or TCR-T, therapies for cancer.
Immunocore Holdings plc
IMCR · Biological Products, (No Diagnostic Substances)
Immunocore Holdings plc is a commercial-stage biotechnology company built around its proprietary ImmTAX platform, which engineers TCR-based medicines to…
Immix Biopharma, Inc.
IMMX · Pharmaceutical Preparations
Immunic, Inc
IMUX · Pharmaceutical Preparations
BriaCell Therapeutics Corp.
BCTXZ · Pharmaceutical Preparations
Janux Therapeutics, Inc.
JANX · Pharmaceutical Preparations
Janux Therapeutics is a clinical-stage biopharmaceutical company developing cancer immunotherapies built on its proprietary TRACTr, TRACIr, and ARM platforms.
Last updated: 28/09/2026